Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database
These findings underscore the necessity of tailored monitoring strategies for carboplatin, taking into account patient sex and age, especially when used in conjunction with immunotherapy. The study's insights support refining pharmacovigilance strategies and updating clinical guidelines to enable early intervention and improve personalized management for patients with NSCLC.
Authors
- Hui Zhao (ORCID: https://orcid.org/0009-0005-1150-943X)
- Peiyun Lv
- Zhe Wang (ORCID: https://orcid.org/0000-0002-7854-8207)
- Lei Wang (ORCID: https://orcid.org/0000-0002-5071-5800)
- Kunpeng Yang
- Chunhui Cai (ORCID: https://orcid.org/0000-0002-1742-4999)
- Wang Bao (ORCID: https://orcid.org/0009-0009-3634-8870)
Institutions
- Jilin Province Tumor Hospital (CN)
- Changchun University of Chinese Medicine (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-06-16
- DOI
- https://doi.org/10.3389/fmed.2025.1590738
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00